Evidence map›Paper›PMID 39244532›Full record

ArticleBMC palliative care2024

A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol.

David A Palma, Meredith E Giuliani, Rohann J M Correa, Famke L Schneiders, Stephen Harrow, Matthias Guckenberger, Tina Zhang, Houda Bahig, Sashendra Senthi, Peter Chung and 16 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC palliative care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05717166 (A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05717166 phase3recruitingnot on this map

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

TypeinterventionalSponsorDavid PalmaRan2023 to 2029Enrolled180ConditionsMetastatic TumorArmsPalliative Radiotherapy, Chemotherapy, Hormone therapy, Immunotherapy, Targeted Systemic Therapy
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Clinical outcomes of stereotactic body radiotherapy in oligometastatic disease: a national real-world cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

David A PalmaDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada. david.palma@lhsc.on.ca.
Meredith E GiulianiDepartment of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Rohann J M CorreaDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Famke L SchneidersDepartment of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands.
Stephen HarrowEdinburgh Cancer Centre, Edinburgh, Scotland.
Matthias GuckenbergerDepartment of Radiation Oncology, Zurich University Hospital, Zurich, Switzerland.
Tina ZhangDepartment of Radiation Oncology, BC Cancer, Vancouver, BC, Canada.
Houda BahigDepartment of Radiation Oncology, Centre Hospitalier de L'Université de Montréal, Montréal, QC, Canada.
Sashendra SenthiAlfred Health Radiation Oncology, Melbourne, Australia.
Peter ChungDepartment of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Robert OlsonDepartment of Radiation Oncology, BC Cancer, Prince George, British Columbia, Canada.
Michael LockDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Srinivas RamanDepartment of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Glenn S BaumanDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Benjamin H LokDepartment of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Joanna M LabaDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Rachel M GlicksmanDepartment of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Timothy K NguyenDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Pencilla LangDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Joelle HelouDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Christopher D GoodmanDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Lucas C MendezDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Peter S N van RossumDepartment of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands.
Andrew WarnerDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Stewart GaedeDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.
Alison L AllanDepartment of Oncology, London Health Sciences Centre, Western University, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging randomized data, mostly from phase II trials, have suggested that patients with oligometastatic cancers may benefit from ablative treatments such as stereotactic ablative radiotherapy (SABR). However, phase III data testing this paradigm are lacking, and many studies have examined SABR in the setting of metachronous oligometastatic disease. The goal of the SABR-SYNC trial is to assess the effect of SABR in patients with oligometastatic cancers and a synchronous primary tumor.

methodsOne hundred and eighty patients will be randomized in a 1:2 ratio between standard of care (SOC) palliative-intent treatments vs. SOC + ablative therapy (SABR preferred) to all sites of known disease. Randomization will be stratified based on histology and number of metastases at enrollment. SABR may be delivered in 1-, 3- and 5-fraction regimens, with recommended doses of 20 Gy, 30 Gy, and 35 Gy, respectively. Non-SABR local modalities (e.g. surgery, thermal ablation, conventional radiation) may be used for treatment of the primary or metastases at the discretion of the treating physicians, if those modalities are clinically preferred. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, time to development of new metastatic lesions, time to initiation of next systemic therapy, quality of life, and toxicity. Translational endpoints include assessment of circulating tumor DNA and immunological predictors of outcomes. DISCUSSION: SABR-SYNC will provide phase III data to assess the impact of SABR on overall survival in a population of patients with synchronous oligometastases. The translational component will attempt to identify novel prognostic and predictive biomarkers to aid in clinical decision making.

trial registrationClinicaltrials.gov NCT05717166 (registration date: Feb. 8, 2023).

Indexed as

RadiosurgeryAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasms, Multiple PrimaryRandomized Controlled Trials as TopicOligometastasesQuality of lifeStereotactic ablative radiotherapySynchronous

Identifiers

PMID39244532
PMCPMC11380777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.